Insider Selling: Nurix Therapeutics (NASDAQ:NRIX) Insider Sells $36,982.44 in Stock

Nurix Therapeutics, Inc. (NASDAQ:NRIX) insider Gwenn Hansen sold 1,452 shares of the stock in a transaction on Tuesday, September 1st. The stock was sold at an average price of $25.47, for a total transaction of $36,982.44. Following the sale, the insider directly owned 117,227 shares of the company’s stock, valued at $2,985,771.69. This represents a 1.22% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Gwenn Hansen also recently made the following trade(s):

• On Wednesday, August 5th, Gwenn Hansen sold 4,356 shares of Nurix Therapeutics stock. The stock was sold at an average price of $25.00, for a total transaction of $108,900.00.
• On Tuesday, August 4th, Gwenn Hansen sold 4,111 shares of Nurix Therapeutics stock. The shares were sold at an average price of $24.36, for a total transaction of $100,143.96.
• On Thursday, July 30th, Gwenn Hansen sold 3,847 shares of Nurix Therapeutics stock. The stock was sold at an average price of $23.38, for a total transaction of $89,942.86.
• On Thursday, June 25th, Gwenn Hansen sold 5,394 shares of Nurix Therapeutics stock. The stock was sold at an average price of $20.00, for a total value of $107,880.00.

Nurix Therapeutics Price Performance

NRIX opened at $25.32 on Friday. The business’s 50-day moving average price is $24.84 and its two-hundred day moving average price is $19.28. Nurix Therapeutics, Inc. has a 1 year low of $8.19 and a 1 year high of $28.23. The company has a market capitalization of $2.63 billion, a price-to-earnings ratio of -7.34 and a beta of 1.80.

Nurix Therapeutics (NASDAQ:NRIX) last posted its quarterly earnings data on Thursday, July 9th. The company reported ($0.81) earnings per share for the quarter, missing the consensus estimate of ($0.73) by ($0.08). The firm had revenue of $9.04 million for the quarter, compared to analyst estimates of $15.29 million. Nurix Therapeutics had a negative return on equity of 76.09% and a negative net margin of 928.44%. Sell-side analysts anticipate that Nurix Therapeutics, Inc. will post -2.73 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the stock. California State Teachers Retirement System increased its position in shares of Nurix Therapeutics by 1,598.1% during the 2nd quarter. California State Teachers Retirement System now owns 1,681,873 shares of the company’s stock worth $40,802,000 after purchasing an additional 1,582,831 shares during the last quarter. Nykredit A S acquired a new stake in shares of Nurix Therapeutics in the 2nd quarter valued at approximately $32,000. Susquehanna Fundamental Investments LLC acquired a new stake in shares of Nurix Therapeutics in the 2nd quarter valued at approximately $341,000. Alyeska Investment Group L.P. bought a new position in shares of Nurix Therapeutics in the second quarter valued at $3,351,000. Finally, Cookson Peirce & Co. Inc. bought a new position in shares of Nurix Therapeutics in the second quarter valued at $558,000.

Analyst Ratings Changes

A number of equities analysts have weighed in on the company. Needham & Company LLC reaffirmed a “buy” rating and set a $34.00 price target on shares of Nurix Therapeutics in a research report on Tuesday, August 4th. Oppenheimer began coverage on shares of Nurix Therapeutics in a report on Monday, June 29th. They issued an “outperform” rating and a $28.00 price objective on the stock. Stifel Nicolaus boosted their price objective on shares of Nurix Therapeutics from $34.00 to $40.00 and gave the stock a “buy” rating in a research report on Friday, July 10th. Wells Fargo & Company cut shares of Nurix Therapeutics from an “overweight” rating to a “hold” rating and reduced their target price for the stock from $28.00 to $25.00 in a report on Monday, June 8th. Finally, HC Wainwright raised their target price on shares of Nurix Therapeutics from $32.00 to $34.00 and gave the company a “buy” rating in a research report on Friday, July 10th. Thirteen equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $34.21.

About Nurix Therapeutics

Nurix Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small-molecule therapies that harness the ubiquitin-proteasome system to selectively degrade disease-causing proteins. By modulating E3 ubiquitin ligases and related molecular machinery, Nurix aims to expand treatment options for patient populations with unmet medical needs in oncology and immunology.

The company’s pipeline includes multiple programs in various stages of development.